A5105665525- Chronic Obstructive Pulmonary Disease (COPD) Research
- Venous Thromboembolism Diagnosis and Management
- Mobile Health and mHealth Applications
- Chronic Disease Management Strategies
- Advanced Breast Cancer Therapies
- Atrial Fibrillation Management and Outcomes
- Retinal Development and Disorders
- Dysphagia Assessment and Management
- Cancer-related Molecular Pathways
- Urinary and Genital Oncology Studies
- Healthcare Systems and Technology
- Clinical practice guidelines implementation
- Retinal Diseases and Treatments
- Hip and Femur Fractures
- Climate Change and Health Impacts
- Agriculture and Farm Safety
- Reproductive tract infections research
- Adolescent Sexual and Reproductive Health
- Syphilis Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Urological Disorders and Treatments
- Bladder and Urothelial Cancer Treatments
- Pediatric Pain Management Techniques
- Asthma and respiratory diseases
- Gastroesophageal reflux and treatments
Cardiff University
2014-2023
University of Birmingham
2010-2016
Hull and East Yorkshire Hospitals NHS Trust
2013
Castle Hill Hospital
2013
Stamford and Rutland Hospital
2009
To determine if self-monitoring via home-based telehealth equipment could, when combined with ongoing remote monitoring by a nurse, reduce the incidence of hospitalizations and emergency department (ED) presentations for people chronic obstructive pulmonary disease (COPD).A randomized controlled trial was used to compare outcomes participants receiving those in an information-only control group, over period 6 months. Participants intervention were taught measure record their vital signs...
<title>Abstract</title> Gemcitabine plus cisplatin (GC) is effective in urothelial and other cancers. We investigated GC combined with escalating doses of temsirolimus (T), intravenous mTOR inhibitor. Adults histologically confirmed solid tumours were enrolled. The primary endpoint was safety T, including dose limiting toxicity. Exploratory endpoints included pharmacokinetics circulating tumour DNA (ctDNA) analyses. Fourteen participants (6 bladder cancer) Four levels evaluated, adverse...
Aim To test the validity, reliability and feasibility of using a modified version Parkes’ (1993) Bereavement Risk Index (BRI) bereavement support protocol in an Australian home hospice care setting. In addition, study aimed to explore what types family members are most likely experience more difficult grief reaction. Design A prospective, descriptive was used. One hundred fifty bereaved participated. Bereaved were classified as high, medium or low risk received structured based on their...
Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to GC (SGC regimen). Overall, 63 treatment-naïve participants were recruited received up six 21-d cycles 70 mg/m2 (intravenously [IV], day 1) gemcitabine 1000 (IV, days 1 8) combined with 37.5 mg (orally, 2–15). Following review toxicity after first patients, dose was...
Venous thromboembolism is common in cancer patients and requires anticoagulation with low-molecular-weight heparin (LMWH). Current data recommend LMWH for as far 6 months, yet guidelines beyond months who have ongoing or active cancer. This recommendation, based on expert consensus, has not been evaluated a clinical study. (1) To identify the most clinically cost-effective length of treatment cancer-associated thrombosis (CAT); (2) to practicalities conducting full randomised controlled...
There is a need for straightforward, novel diagnostic and monitoring technologies to enable the early diagnosis of COPD its differentiation from other respiratory diseases, establish cause acute exacerbations monitor disease progression. We sought whether already in development could potentially address these needs. A systematic horizon scanning review was undertaken identify wide range commercial non-commercial sources. Technologies were restricted those likely be available within 18...
Chronic cough is a common and distressing symptom. Gastro-oesophageal reflux cause of chronic however the symptom complex in not confined to classic peptic symptoms. Dyspeptic symptoms have previously been shown respond dietary modifications weight loss. We hypothesised that reduction maybe useful non-pharmacological strategy reducing obese. Subjects with were recruited from Hull Cough Clinic. They randomised one two open parallel groups; receiving traditional other advice form an Energy...
Venous thromboembolism is common in patients with cancer and requires anticoagulation low molecular weight heparin. Current data informs as far six months, yet guidelines recommend beyond months who have locally advanced or metastatic cancer. This recommendation, based on expert consensus, has not been evaluated a clinical study. ALICAT (Anticoagulation Length Cancer Associated Thrombosis) feasibility study to identify the most clinically cost effective length of heparin treatment associated...
Introduction Medical patients, admitted acutely to hospital, are at risk of venous thromboembolism (VTE). Clinical guidelines advise thromboprophylaxis prophylaxis for those high VTE. VTE is a common sequela cancer, but take little consideration cancer as an independent factor and their utility in palliative care patients unclear. The hospice inpatient deep vein thrombosis (DVT) detection study (HIDDen) reported 28% prevalence asymptomatic iliofemoral DVT poor performance status (PS)...
Chlamydia trachomatis (chlamydia) is the most common bacterial sexually transmitted infection (STI). Its incidence in UK has risen steadily since mid-1990s, with new diagnoses rising by 1% from 121 791 to 123 018 (from 197 199 per 100 000 population) between 2007 and 2008.1 Generally rates of chlamydia infections other Western European countries are lower than those UK. Young people aged under 25 years likely be infected, 65% (80 258) all 2008 individuals ages 16 24 years.2 The re-infection...
Abstract Background FURVA, a randomised, double-blind Phase II trial, investigated whether the addition of vandetanib to fulvestrant improved progression-free survival (PFS) in patients with an aromatase inhibitor(AI)-resistant advanced breast cancer. Methods Postmenopausal women oestrogen receptor-positive (ER+ve)/HER2-negative cancer, who experienced disease progression on AI, were randomised (1:1) 500 mg (Q28) 300 od (f + v) or placebo p) until discontinuation. The primary endpoint was...
Aim: To investigate the osteoporosis risk profile of older home care clients and prevalence fracture treatment within this group. Methods: A total 1500 were randomly selected mailed a survey. Overall, 874 (58%) those surveyed completed returned Results: third (37%, n = 318) reported at least one 871(99.7%) factor for osteoporosis. Despite only 28% diagnosis osteoporosis, which was more likely if they had sustained fracture. Bone mineral density tests by 37.4% respondents 51.9% who fractured....